Eagle Global Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Eagle Global Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,565	Closed	-$281K	–	246
2022 Q1	$281K	Sell	8,565 -3,520	-29%	-$104K	0.02%	205
2021 Q4	$319K	Sell	12,085 -47,690	-80%	-$3.69M	0.02%	201
2021 Q3	$6.01M	Buy	59,775 +25,420	+74%	+$2.98M	0.4%	70
2021 Q2	$4.86M	Buy	34,355 +8,550	+33%	+$965K	0.31%	82
2021 Q1	$2.57M	Buy	25,805 +1,015	+4%	+$118K	0.19%	96
2020 Q4	$3.06M	Buy	24,790 +2,810	+13%	+$369K	0.24%	88
2020 Q3	$2.14M	Buy	21,980 +2,480	+13%	+$310K	0.19%	95
2020 Q2	$3.04M	Buy	19,500 +11,450	+142%	+$1.74M	0.27%	83
2020 Q1	$1.16M	Buy	8,050 +550	+7%	+$106K	0.12%	118
2019 Q4	$1.53M	Hold	7,500	–	–	0.08%	133
2019 Q3	$602K	Hold	7,500	–	–	0.03%	154
2019 Q2	$708K	Buy	7,500 +1,100	+17%	+$95K	0.03%	155
2019 Q1	$547K	Buy	6,400 +400	+7%	+$33.2K	0.02%	165
2018 Q4	$337K	Buy	+6,000	New	+$366K	0.01%	181

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eagle Global Advisors's RETA Position: Q2 2022 in Review

Eagle Global Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2022, closing a stake of 8,565 shares — an estimated $281K sold.

Eagle Global Advisors first reported a position in RETA in Q4 2018 and held it in 14 quarters. The position peaked at $6.01M in Q3 2021. 146 funds tracked by Wall St. Rank hold RETA as of Q2 2022.

Eagle Global Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2022 after selling out during the quarter.
Eagle Global Advisors sold 8,565 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2022, an estimated $281K.
Eagle Global Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2018 and held it in 14 quarters.
Eagle Global Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $6.01M in Q3 2021.
146 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2022.

Based on Eagle Global Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.